The pathogenesis, treatment and prevention of osteoporosis in men

Drugs

Volumn 73, Issue 1, 2013, Pages 15-29

  Mosekilde, Leif ^a,b   Vestergaard, Peter ^b   Rejnmark, Lars ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; ESTROGEN; FINASTERIDE; GROWTH HORMONE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PRASTERONE; RISEDRONIC ACID; SALCATONIN; SOMATOMEDIN; TESTOSTERONE; TESTOSTERONE ENANTATE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MASS; BONE STRUCTURE; BONE TURNOVER; CONSTIPATION; ECZEMA; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGONADISM; MALE; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; RHINOPHARYNGITIS; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; VITAMIN SUPPLEMENTATION;

AGE FACTORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS; TESTOSTERONE; TIME FACTORS;

EID: 84877022835     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-012-0003-1     Document Type: Article

References (114)

1. Cummings SR, Cawthon PM, Ensrud KE, Osteoporotic Fractures in Men (MrOS) Research Groups, Study of Osteoporotic Fractures Research Groups, et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res. 2006;1:1550-6.
2. Seeman E. Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord. 2001;2:45-64.
3. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int. 2005;16:134-41.
4. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. Geneva: WHO; 1994.
5. Kanis JA, Bianchi G, Bilezikian JP, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789-98.
6. Kanis JA, Johnell O, Oden A, et al. Risk of hip fractures according to World Health Organisation criteria for osteoporosis and osteopenia. Bone. 2000;27:585-90.
7. McCloskey EV, Binkley N, FRAX(®) Position Development Conference Members. FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom. 2011;14(3):181-3.
8. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581-9.
9. Schwarz P, Jørgensen NR, Mosekilde L, et al. The evidence for efficacy of osteoporosis treatment in men - a systematic review and metaanalysis of antiresorptive and anabolic treatments in men. Epub: J Osteoporos; 2011.
10. Davies KM, Stegman MR, Heaney RP, et al. Prevalence and severity of vertebral fracture: the Saunders County Bone Quality Study. Osteoporos Int. 1996;6:160-5.
11. Jones G, Nguyen T, Sambrook PN, et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int. 1994;4:277-82.
12. Hasserius R, Karlsson MK, Nilsson BE, et al. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int. 2003;14:61-8.
13. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82.
14. Adachi JD, Ioannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2001;12:903-8.
15. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407-13.
16. Trombetti A, Herrmann F, Hoffmeyer P, et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int. 2002;13:731-7.
17. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone. 2003;32:468-73.
18. Vestergaard P, Rejnmark L, Mosekilde L. Loss of life-years after a hip fracture. Acta Orthop. 2009;80(5):525-30.
19. Kanis JA, Glüer CC, For the committee of Scientific Advisors. International Osteoporosis Foundation: an update of the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000;11:192-202.
20. Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42:467-75.
21. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;1:1761-8.
22. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
23. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010;25(7):1506-11.
24. Garn SM. The earlier gain and later loss of cortical bone. Springfield: CC Thomas Publishers; 1970.
25. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev. 1995;16:87-116.
26. Legroux-Gerot I, Blanckaert F, Solau-Gervais E, et al. Causes of osteoporosis in males. A review of 160 cases. Rev Rhum Engl Ed. 1999;66:404-9.
27. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453-68.
28. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
29. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin N Am. 2003;32:115-34.
30. Orwig DL, Chiles N, Jones M, et al. Osteoporosis in men: update 2011. Rheum Dis Clin North Am. 2011;37(3):401-14.
31. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:737-42.
32. Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone. 1994;15:551-5.
33. Cawthon PM, Harrison SL, Barrett-Connor E, et al. Alcohol intake and its relationship with bone mineral density, falls, and fracture risk in older men. J Am Geriatr Soc. 2006;54:1649-57.
34. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-64.
35. Clarke BL, Khosla S. Androgens and bone. Steroids. 2009;74:296-305.
36. Khosla S, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone in circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002;87:1550-4.
37. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95:3-10.
38. Falathi-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553-60.
39. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab. 2001;86:192-9.
40. Guo C, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism: effect on bone mineral density and bone turnover. J Clin Endocrinol Metab. 1997;82:658-65.
41. Finkelstein J, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987;106:354-61.
42. Finkelstein J, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med. 1992;326:600-4.
43. Finkelstein J, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab. 1996;81:1152-5.
44. Bertelloni S, Baroncelli GI, Battini R, et al. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res. 1995;10:1488-95.
45. Stoch S, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787-91.
46. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med. 1989;110:430-6.
47. Orwig DL, Chiles N, Jones M, et al. Osteoporosis in men: update 2011. Rheum Dis Clin N Am. 2011;37:401-14.
48. Fink H, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91:3908-15.
49. Mellstrom D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21:529-35.
50. Ensrud K, Lewis CE, Lambert LC, Osteoporotic Fractures in Men MrOS Study Research Group, et al. Endogenous sex steroids, weight change and rates of hip bone loss in older men: the MrOS study. Osteoporos Int. 2006;17:1329-36.
51. Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men. Arch Intern Med. 2008;168:47-54.
52. Araujo A, Travison TG, Leder BZ, et al. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab. 2008;93:2135-41.
53. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive associations with serum estrogens and negative associations with androgens. J Clin Invest. 1997;100:1755-9.
54. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol. 1998;49:803-9.
55. Center J, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab. 1999;84:3626-35.
56. Greendale G, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res. 1997;12:1833-43.
57. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann Intern Med. 2000;133:951-63.
58. Meier D, Orwoll ES, Keenan EJ, et al. Marked decline in trabecular bone mineral content in healthy men with age: lack of association with sex steroid levels. J Am Geriatr Soc. 1987;35:189-97.
59. Rudman D, Drinka PJ, Wilson CR, et al. Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men. Clin Endocrinol. 1994;40:653-61.
60. Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006;119:426-33.
61. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336-44.
62. Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1989;83:2266-74.
63. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res. 1997;12(11):1833-43.
64. van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85(9):3276-82.
65. Khosla S, Melton LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555-61.
66. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:219-23.
67. Francis RM. The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf). 1999;50:411-4.
68. Szulc P, Munoz F, Marchand F, et al. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int. 2003;73:520-30.
69. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
70. Saquib N, von Mühlen D, Garland CF, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporos Int. 2006;17:1734-41.
71. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res. 2000;15:323-31.
72. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69:1-19.
73. Rejnmark L, Vestergaard P, Broot C, et al. Increased fracture risk in normocalcemic postmenopausal women with high parathyroid hormone levels: a 16-year follow-up study. Calcif Tiss Int. 2011;88:238-45.
74. Scane A, Sutcliffe AM, Francis RM. Osteoporosis in men. Bailliere's Clin Rheumatol. 1993;7:589-601.
75. Arisaka O, Arisaka M, Nakayama Y, et al. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. Metabolism. 1995;44:419-23.
76. van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med. 1992;41:259-63.
77. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-59.
78. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-10.
79. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation on bone loss and fractures in people aged 50 years and older: a meta-analysis. Lancet. 2007;307:657-66.
80. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92:1415-23.
81. D.I.P.A.R.T Group, Abrahamsen B, Masud T, Avenell A, et al. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463.
82. Boland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;29(341):c3691.
83. Boland MJ, Grey AB, Gamble GD, et al. Calcium and vitamin D supplements and health outcomes: reanalyses of the Women's Health Initiative (WHI) limited access data set. Am J Clin Nutr. 2011;94:1144-9.
84. Wallace RB, Wactawski-Wende J, O'Sullivan MJ, et al. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr. 2011;94:270-7.
85. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. JBMR. 2011;26:35-41.
86. Paik J, Rexrode K, Taylor E, et al. A prospective study of calcium supplement intake and risk of cardiovascular disease in women [abstract no. 1135]. Minneapolis: American Society for Bone and Mineral Research annual meeting; 2012.
87. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med. 1993;328:833-8.
88. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk of kidney stones for women. Ann Intern Med. 1997;126:497-504.
89. Curhan GC, Willets WC, Knight EL, et al. Dietary factors and the risk of incident kidney stones in younger women: Nurses Health study II. Arch Intern Med. 2004;164:885-91.
90. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009;2:CD000227.
91. Bjelakovic G, Gluud LL, Nikolova D et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011;(7):CD007470.
92. Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab. 2012;97(8):2670-81.
93. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Eng J Med. 2000;343:604-10.
94. Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tiss Int. 2003;73:133-9.
95. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24:719-25.
96. Orwoll ES, Binkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010;46:970-6.
97. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;10:2239-50.
98. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res. 2002;17:521-7.
99. Orwoll E, Teglbjaerg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (Epub 21 Jun 2012).
100. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
101. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-76.
102. Lyles KW, Cathleen S, Colon-Emeric CS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809.
103. Rejnmark L, Mosekilde L. New and emerging antiresorptive treatments in osteoporosis. Curr Drug Saf. 2011;6:75-88.
104. Mosekilde L, Tørring O, Rejnmark L. Emerging anabolic treatments in osteoporosis. Curr Drug Saf. 2011;6:62-74.
105. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide (human parathyroid hormone). Osteoporos Int. 2004;15:992-7.
106. Adler RA, Hochberg MC. Glucocorticoid-induced osteoporosis in men. Endocrinol Invest. 2011;34:481-4.
107. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-26.
108. Saag KG, Zanchetta JR, Devogelae J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-55.
109. Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid treated men. Arch Intern Med. 1996;15:1173-7.
110. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. Clin Endocrinol Metab. 2005;90:6410-7.
111. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-24.
112. Smith MR, Malkowicz SB, Brawer MK, et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011;186:2239-44.
113. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
114. Papaioannou A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int. 2009;20:507-18.